Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

1.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive NSCLC.

Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2015 Aug 25. [Epub ahead of print]

PMID:
26309191
2.

Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al.

Pujol JL, Morin F, Zalcman G; IFCT.

Ann Oncol. 2015 Aug 7. pii: mdv292. [Epub ahead of print] No abstract available.

PMID:
26254441
3.

Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer.

Lamy PJ, Plassot C, Pujol JL.

PLoS One. 2015 Jun 1;10(6):e0128836. doi: 10.1371/journal.pone.0128836. eCollection 2015.

4.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):783-90. doi: 10.1093/icvts/ivv050. Epub 2015 Mar 11.

5.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT); French Cooperative Thoracic Intergroup IFCT.

Ann Oncol. 2015 May;26(5):908-14. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.

PMID:
25688059
6.

Perception of lung cancer among the general population and comparison with other cancers.

Mazières J, Pujol JL, Kalampalikis N, Bouvry D, Quoix E, Filleron T, Targowla N, Jodelet D, Milia J, Milleron B.

J Thorac Oncol. 2015 Mar;10(3):420-5. doi: 10.1097/JTO.0000000000000433.

PMID:
25514806
7.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators.

N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.

8.

High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers.

Makinson A, Hayot M, Eymard-Duvernay S, Quesnoy M, Raffi F, Thirard L, Bonnet F, Tattevin P, Abgrall S, Quantin X, Léna H, Bommart S, Reynes J, Le Moing V; ANRS EP48 HIV CHEST Study Team.

Eur Respir J. 2015 Mar;45(3):828-31. doi: 10.1183/09031936.00154914. Epub 2014 Oct 16. No abstract available.

PMID:
25323226
9.

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C.

Clin Lung Cancer. 2014 Nov;15(6):418-25. doi: 10.1016/j.cllc.2014.06.007. Epub 2014 Jun 21.

10.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

Scagliotti GV, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson PM, John W, Chouaki N, Visseren-Grul C, Paz-Ares LG.

Lung Cancer. 2014 Sep;85(3):408-14. doi: 10.1016/j.lungcan.2014.07.005. Epub 2014 Jul 16.

PMID:
25088661
11.

Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.

Gridelli C, de Marinis F, Thomas M, Prabhash K, El Kouri C, Blackhall F, Bustin F, Pujol JL, John WJ, San Antonio B, Zimmermann A, Chouaki N, Visseren-Grul C, Paz-Ares LG.

J Thorac Oncol. 2014 Jul;9(7):991-7. doi: 10.1097/JTO.0000000000000207.

PMID:
24926544
12.

[One more word about the diagnostic. A metapsychological approach].

Pujol JL, Mérel JP.

Rev Mal Respir. 2014 Apr;31(4):347-56. doi: 10.1016/j.rmr.2013.11.008. Epub 2014 Mar 12. Review. French.

PMID:
24750954
13.

[Delays for lung cancer treatment: performance with respect to timeliness and increase of investigations].

Pujol JL.

Rev Mal Respir. 2014 Mar;31(3):198-202. doi: 10.1016/j.rmr.2013.11.003. Epub 2013 Dec 12. French. No abstract available.

14.

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N.

Lung Cancer. 2014 Feb;83(2):211-8. doi: 10.1016/j.lungcan.2013.11.006. Epub 2013 Nov 16.

PMID:
24332319
15.

Impact of preoperative marking coils on surgical and pathologic management of impalpable lung nodules.

Bommart S, Bourdin A, Marin G, Berthet JP, Pujol JL, Serre I, Molinari N, Marty-Ané C, Kovacsik H.

Ann Thorac Surg. 2014 Feb;97(2):414-8. doi: 10.1016/j.athoracsur.2013.09.041. Epub 2013 Dec 7.

PMID:
24315138
16.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Eur Respir J. 2014 Jan;43(1):240-9. doi: 10.1183/09031936.00048213. Epub 2013 Oct 10.

17.

[Anti-Hu antibodies: a remarkable immulogical phenotype for several paraneoplastic syndromes].

Pujol JL, Di Mercurio JP, Carlander B.

Rev Mal Respir. 2013 Sep;30(7):521-3. doi: 10.1016/j.rmr.2013.05.006. Epub 2013 Jun 21. French. No abstract available.

PMID:
24034454
18.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.

J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.

19.

Management of part-solid nodules.

Bommart S, Kovacsik HV, Pujol JL.

Radiology. 2013 Jul;268(1):306. doi: 10.1148/radiol.13130293. No abstract available.

PMID:
23793596
20.

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

Westeel V, Quoix E, Puyraveau M, Lavolé A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Rivière A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarié E, Morin F, Depierre A, Milleron B; Intergroupe Francophone de Cancérologie Thoracique.

Eur J Cancer. 2013 Aug;49(12):2654-64. doi: 10.1016/j.ejca.2013.04.013. Epub 2013 Jun 1.

PMID:
23735703
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk